<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100944">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066259</url>
  </required_header>
  <id_info>
    <org_study_id>OctavaColon_001</org_study_id>
    <nct_id>NCT02066259</nct_id>
  </id_info>
  <brief_title>OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol</brief_title>
  <official_title>OctavaColon Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eventus Diagnostics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eventus Diagnostics Ltd</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OctavaColon tests are qualitative plasma tests that are indicated to people above 18
      years of age suspected with colon abnormality. The blood tests will provide additional
      information to the doctor in the course of colon cancer diagnosis for both normal population
      and high risk population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical objective of this study is to develop two antibody-based blood tests for
      additional information during colon cancer diagnosis -

        1. Highly specific (OctavaGold) - provides additional information to doctors during
           evaluation of normal population.

        2. Highly sensitive (OctavaSilver) - provides additional information to doctors during
           evaluation of high risk population.

      The study will be considered successful it can achieve at least one of the following sets of
      performances -

        1. For the OctavaGold - 95% specificity with at least 50% sensitivity.

        2. For the OctavaSilver - 95% sensitivity with at least 50% specificity. The biological
           objective of this study is to find the best set of antigens, that when combined with
           the appropriate algorithm will support each of the above clinical objectives
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Number of participants in each of the clinicaly defined groups (0,1 and 2).</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>healthy_0</arm_group_label>
    <description>healthy, people with normal (negative) colonoscopy results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patient_1</arm_group_label>
    <description>people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign_2</arm_group_label>
    <description>people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        There are 3 different populations that will participate in the study-

          1. Any person with suspected colon abnormality, that will be classified after
             colonoscopy/surgery as &quot;colon cancer patient&quot; will be a part of group1 - &quot;Patient&quot;.

          2. Any person with suspected colon abnormality, that will be classified after
             colonoscopy as &quot;benign polyp&quot; will be a part of group2 - &quot;benign&quot;.

          3. Any person with suspected colon abnormality, that will be classified after
             colonoscopy as &quot;normal/healthy&quot; will be a part of group0 - &quot;healthy&quot;.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects 18 years or over. Subjects scheduled for colonoscopy or surgery

        Exclusion Criteria:

          -  Subjects less than 18 years of age

          -  Previous or concurrent synchronous cancers other than previous malignancies of the
             colon and recovered melanoma

          -  Autoimmune disorders diagnosed subjects

          -  Hematological malignancies

          -  Subjects under active chemotherapy treatment or chemotherapy in the past 6 months

          -  Steroid treatment in the past 3 months

          -  Subject undergoing immunosuppressive treatments

          -  Subject with verified melanoma colon cancer

          -  Subject with verified sarcoma colon cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Galit Yahalom, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Eventus Dx</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galit Yahalom, Ph.D</last_name>
    <phone>+972546922422</phone>
    <email>galit@eventusdx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>85025</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilbert Sabag, MD</last_name>
      <email>GilbertS@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Gilbert Sabag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Carmel&quot; Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arie Bitterman, MD</last_name>
      <email>bitterman@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Arie Bitterman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilly Merdler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dabbah Kamal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Tel hashomer</name>
      <address>
        <city>Ramat gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adi Lahat, MD</last_name>
      <email>Adi.Lahat@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Adi Lahat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013.</citation>
    <PMID>24324350</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>February 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>cancer associated auto antibodies</keyword>
  <keyword>colon cancer blood test</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
